Ramatroban: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Ramatroban": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
 
Line 30: Line 30:
{{CMG}}
{{CMG}}


{{EH}}
 


'''Ramatroban''' ([[International Nonproprietary Name|INN]]) is a thromboxane receptor antagonist indicated for the treatment of coronary artery disease.<ref name="pmid2260140">{{cite journal |author=Fiedler VB, Seuter F, Perzborn E |title=Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease |journal=Stroke |volume=21 |issue=12 Suppl |pages=IV149–51 |year=1990 |month=December |pmid=2260140 |doi= |url=}}</ref> It has also been used for the treatment of [[asthma]].<ref name="pmid8950952">{{cite journal |author=Endo S, Akiyama K |title=[Thromboxane A2 receptor antagonist in asthma therapy] |language=Japanese |journal=Nippon Rinsho |volume=54 |issue=11 |pages=3045–8 |year=1996 |month=November |pmid=8950952 |doi= |url=}}</ref>
'''Ramatroban''' ([[International Nonproprietary Name|INN]]) is a thromboxane receptor antagonist indicated for the treatment of coronary artery disease.<ref name="pmid2260140">{{cite journal |author=Fiedler VB, Seuter F, Perzborn E |title=Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease |journal=Stroke |volume=21 |issue=12 Suppl |pages=IV149–51 |year=1990 |month=December |pmid=2260140 |doi= |url=}}</ref> It has also been used for the treatment of [[asthma]].<ref name="pmid8950952">{{cite journal |author=Endo S, Akiyama K |title=[Thromboxane A2 receptor antagonist in asthma therapy] |language=Japanese |journal=Nippon Rinsho |volume=54 |issue=11 |pages=3045–8 |year=1996 |month=November |pmid=8950952 |doi= |url=}}</ref>

Latest revision as of 15:32, 20 August 2012

Ramatroban
Clinical data
Routes of
administration		Oral
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H21FN2O4S
Molar mass416.46 g/mol
3D model (JSmol)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Ramatroban (INN) is a thromboxane receptor antagonist indicated for the treatment of coronary artery disease.[1] It has also been used for the treatment of asthma.[2]

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the tradename Baynas.

References

  1. ↑ Fiedler VB, Seuter F, Perzborn E (1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease". Stroke. 21 (12 Suppl): IV149–51. PMID 2260140. Unknown parameter |month= ignored (help)
  2. ↑ Endo S, Akiyama K (1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nippon Rinsho (in Japanese). 54 (11): 3045–8. PMID 8950952. Unknown parameter |month= ignored (help)

Template:Asthma and copd rx

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Ramatroban&oldid=687575"